Author

Marieke Pierik

PRIMARY STUDY RESULTS FROM GO OBSERVE: A REAL-WORLD EUROPEAN PROSPECTIVE SINGLE-ARM OBSERVATIONAL COHORT STUDY OF PATIENT-REPORTED CONTINUOUS CLINICAL RESPONSE TO GOLIMUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
PRIMARY STUDY RESULTS FROM GO OBSERVE: A REAL-WORLD EUROPEAN PROSPECTIVE SINGLE-ARM OBSERVATIONAL COHORT STUDY OF PATIENT-REPORTED CONTINUOUS CLINICAL RESPONSE TO GOLIMUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Marieke Pierik  et al.

DIETARY INTAKE IS ASSOCIATED WITH FLARE DEVELOPMENT IN IBD PATIENTS
DIETARY INTAKE IS ASSOCIATED WITH FLARE DEVELOPMENT IN IBD PATIENTS

Marieke Pierik  et al.

DIETARY DICARBONYLS AND INTESTINAL INFLAMMATION IN INFLAMMATORY BOWEL DISEASE AND IRRITABLE BOWEL SYNDROME PATIENTS
DIETARY DICARBONYLS AND INTESTINAL INFLAMMATION IN INFLAMMATORY BOWEL DISEASE AND IRRITABLE BOWEL SYNDROME PATIENTS

Marieke Pierik  et al.

USTEKINUMAB TROUGH CONCENTRATIONS ARE ASSOCIATED WITH BIOCHEMICAL OUTCOMES IN PATIENTS WITH CROHN’S DISEASE
USTEKINUMAB TROUGH CONCENTRATIONS ARE ASSOCIATED WITH BIOCHEMICAL OUTCOMES IN PATIENTS WITH CROHN’S DISEASE

Marieke Pierik  et al.

THE RISK OF MILD, MODERATE AND SEVERE INFECTIONS IN IBD PATIENTS: RESULTS FROM A PROSPECTIVE, MULTICENTRE, OBSERVATIONAL COHORT STUDY - PRIQ
THE RISK OF MILD, MODERATE AND SEVERE INFECTIONS IN IBD PATIENTS: RESULTS FROM A PROSPECTIVE, MULTICENTRE, OBSERVATIONAL COHORT STUDY - PRIQ

Marieke Pierik  et al.

DEVELOPMENT AND VALIDATION OF A REMOTE MONITORING TOOL FOR REAL-WORLD ASSESSMENT OF MILD, MODERATE, AND SEVERE INFECTIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS
DEVELOPMENT AND VALIDATION OF A REMOTE MONITORING TOOL FOR REAL-WORLD ASSESSMENT OF MILD, MODERATE, AND SEVERE INFECTIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS

Marieke Pierik  et al.

COST-EFFECTIVENESS ANALYSIS OF INCREASED ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: ECONOMIC EVALUATION OF THE RANDOMISED CONTROLLED LADI TRIAL
COST-EFFECTIVENESS ANALYSIS OF INCREASED ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: ECONOMIC EVALUATION OF THE RANDOMISED CONTROLLED LADI TRIAL

Marieke Pierik  et al.

CLINICAL OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: THE RANDOMISED CONTROLLED LADI TRIAL
CLINICAL OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: THE RANDOMISED CONTROLLED LADI TRIAL

Marieke Pierik  et al.

SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY
SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY

Marieke Pierik  et al.

Item 1 - 9 / 9
1